Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention

Abstract Background Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC). However, SP efficacy is threatened by drug resistance, that is conferred by mutations in the dhfr and dhps genes. The World Heal...

Full description

Bibliographic Details
Main Authors: Marit van Lenthe, Renske van der Meulen, Maryvonne Lassovski, Adelaide Ouabo, Edwige Bakula, Colette Badio, Deogratias Cibenda, Lucy Okell, Erwan Piriou, Lynn Grignard, Kjerstin Lanke, Bhargavi Rao, Teun Bousema, Cally Roper
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Malaria Journal
Subjects:
DRC
Online Access:https://doi.org/10.1186/s12936-019-3057-7
id doaj-43dc475688694ee4afe33ba734387cbc
record_format Article
spelling doaj-43dc475688694ee4afe33ba734387cbc2020-12-20T12:39:01ZengBMCMalaria Journal1475-28752019-12-011811910.1186/s12936-019-3057-7Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemopreventionMarit van Lenthe0Renske van der Meulen1Maryvonne Lassovski2Adelaide Ouabo3Edwige Bakula4Colette Badio5Deogratias Cibenda6Lucy Okell7Erwan Piriou8Lynn Grignard9Kjerstin Lanke10Bhargavi Rao11Teun Bousema12Cally Roper13Médecins Sans Frontières (MSF)Médecins Sans Frontières (MSF)MSFMSFMSFMSFProgramme National de Lutte contre le Paludisme (PNLP) South KivuImperial CollegeMédecins Sans Frontières (MSF)London School of Hygiene and Tropical MedicineRadboud University Medical CentreMSFRadboud University Medical CentreLondon School of Hygiene and Tropical MedicineAbstract Background Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC). However, SP efficacy is threatened by drug resistance, that is conferred by mutations in the dhfr and dhps genes. The World Health Organization has specified that intermittent preventive treatment for infants (IPTi) with SP should be implemented only if the prevalence of the dhps K540E mutation is under 50%. There are limited current data on the prevalence of resistance-conferring mutations available from Eastern DRC. The current study aimed to address this knowledge gap. Methods Dried blood-spot samples were collected from clinically suspected malaria patients [outpatient department (OPD)] and pregnant women attending antenatal care (ANC) in four sites in North and South Kivu, DRC. Quantitative PCR (qPCR) was performed on samples from individuals with positive and with negative rapid diagnostic test (RDT) results. Dhps K450E and A581G and dhfr I164L were assessed by nested PCR followed by allele-specific primer extension and detection by multiplex bead-based assays. Results Across populations, Plasmodium falciparum parasite prevalence was 47.9% (1160/2421) by RDT and 71.7 (1763/2421) by qPCR. Median parasite density measured by qPCR in RDT-negative qPCR-positive samples was very low with a median of 2.3 parasites/µL (IQR 0.5–25.2). Resistance genotyping was successfully performed in RDT-positive samples and RDT-negative/qPCR-positive samples with success rates of 86.2% (937/1086) and 55.5% (361/651), respectively. The presence of dhps K540E was high across sites (50.3–87.9%), with strong evidence for differences between sites (p < 0.001). Dhps A581G mutants were less prevalent (12.7–47.2%). The dhfr I164L mutation was found in one sample. Conclusions The prevalence of the SP resistance marker dhps K540E exceeds 50% in all four study sites in North and South Kivu, DRC. K540E mutations regularly co-occurred with mutations in dhps A581G but not with the dhfr I164L mutation. The current results do not support implementation of IPTi with SP in the study area.https://doi.org/10.1186/s12936-019-3057-7MalariaDRCSulfadoxine–pyrimethamine (SP)Chemoprophylaxisdhpsdhfr
collection DOAJ
language English
format Article
sources DOAJ
author Marit van Lenthe
Renske van der Meulen
Maryvonne Lassovski
Adelaide Ouabo
Edwige Bakula
Colette Badio
Deogratias Cibenda
Lucy Okell
Erwan Piriou
Lynn Grignard
Kjerstin Lanke
Bhargavi Rao
Teun Bousema
Cally Roper
spellingShingle Marit van Lenthe
Renske van der Meulen
Maryvonne Lassovski
Adelaide Ouabo
Edwige Bakula
Colette Badio
Deogratias Cibenda
Lucy Okell
Erwan Piriou
Lynn Grignard
Kjerstin Lanke
Bhargavi Rao
Teun Bousema
Cally Roper
Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention
Malaria Journal
Malaria
DRC
Sulfadoxine–pyrimethamine (SP)
Chemoprophylaxis
dhps
dhfr
author_facet Marit van Lenthe
Renske van der Meulen
Maryvonne Lassovski
Adelaide Ouabo
Edwige Bakula
Colette Badio
Deogratias Cibenda
Lucy Okell
Erwan Piriou
Lynn Grignard
Kjerstin Lanke
Bhargavi Rao
Teun Bousema
Cally Roper
author_sort Marit van Lenthe
title Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention
title_short Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention
title_full Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention
title_fullStr Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention
title_full_unstemmed Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention
title_sort markers of sulfadoxine–pyrimethamine resistance in eastern democratic republic of congo; implications for malaria chemoprevention
publisher BMC
series Malaria Journal
issn 1475-2875
publishDate 2019-12-01
description Abstract Background Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC). However, SP efficacy is threatened by drug resistance, that is conferred by mutations in the dhfr and dhps genes. The World Health Organization has specified that intermittent preventive treatment for infants (IPTi) with SP should be implemented only if the prevalence of the dhps K540E mutation is under 50%. There are limited current data on the prevalence of resistance-conferring mutations available from Eastern DRC. The current study aimed to address this knowledge gap. Methods Dried blood-spot samples were collected from clinically suspected malaria patients [outpatient department (OPD)] and pregnant women attending antenatal care (ANC) in four sites in North and South Kivu, DRC. Quantitative PCR (qPCR) was performed on samples from individuals with positive and with negative rapid diagnostic test (RDT) results. Dhps K450E and A581G and dhfr I164L were assessed by nested PCR followed by allele-specific primer extension and detection by multiplex bead-based assays. Results Across populations, Plasmodium falciparum parasite prevalence was 47.9% (1160/2421) by RDT and 71.7 (1763/2421) by qPCR. Median parasite density measured by qPCR in RDT-negative qPCR-positive samples was very low with a median of 2.3 parasites/µL (IQR 0.5–25.2). Resistance genotyping was successfully performed in RDT-positive samples and RDT-negative/qPCR-positive samples with success rates of 86.2% (937/1086) and 55.5% (361/651), respectively. The presence of dhps K540E was high across sites (50.3–87.9%), with strong evidence for differences between sites (p < 0.001). Dhps A581G mutants were less prevalent (12.7–47.2%). The dhfr I164L mutation was found in one sample. Conclusions The prevalence of the SP resistance marker dhps K540E exceeds 50% in all four study sites in North and South Kivu, DRC. K540E mutations regularly co-occurred with mutations in dhps A581G but not with the dhfr I164L mutation. The current results do not support implementation of IPTi with SP in the study area.
topic Malaria
DRC
Sulfadoxine–pyrimethamine (SP)
Chemoprophylaxis
dhps
dhfr
url https://doi.org/10.1186/s12936-019-3057-7
work_keys_str_mv AT maritvanlenthe markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT renskevandermeulen markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT maryvonnelassovski markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT adelaideouabo markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT edwigebakula markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT colettebadio markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT deogratiascibenda markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT lucyokell markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT erwanpiriou markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT lynngrignard markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT kjerstinlanke markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT bhargavirao markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT teunbousema markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
AT callyroper markersofsulfadoxinepyrimethamineresistanceineasterndemocraticrepublicofcongoimplicationsformalariachemoprevention
_version_ 1724376240816652288